Trials / Sponsors / Clene Nanomedicine

Clene Nanomedicine

Industry · 12 registered clinical trials.

Status	Trial	Phase	Started
Active Not Recruiting	An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on S Amyotrophic Lateral Sclerosis	Phase 2	2021-11-13
Completed	Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants Covid19	Phase 2	2021-06-01
Completed	A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Scl Relapsing Multiple Sclerosis	Phase 2 / Phase 3	2020-10-22
Withdrawn	31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Scler Amyotrophic Lateral Sclerosis	Phase 2	2020-03-01
Completed	Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS) Amyotrophic Lateral Sclerosis	Phase 2	2019-12-19
Completed	31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis. Multiple Sclerosis	Phase 2	2019-12-19
Completed	31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease Parkinson's Disease	Phase 2	2019-12-19
Terminated	Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis Relapsing Remitting Multiple Sclerosis, Optic Neuropathy, Optic; Neuritis, With Demyelination	Phase 2	2018-11-23
Completed	A Phase I SAD and MAD Clinical Trial of CNM-Au8 in Healthy Male and Female Volunteers Healthy Volunteers - Male and Female	Phase 1	2015-04-01
Temporarily Not Available	Intermediate Expanded Access Protocol CNMAu8.EAP03 Multiple Sclerosis	—	—
Temporarily Not Available	Intermediate Expanded Access Protocol CNMAu8.EAP04 ALS, Amyotrophic Lateral Sclerosis, PALS	—	—
No Longer Available	Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and CNMAu8.EAP02 for ALS Amyotrophic Lateral Sclerosis	—	—